Your browser doesn't support javascript.
loading
Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy.
Limoli, Paolo Giuseppe; Limoli, Celeste; Vingolo, Enzo Maria; Franzone, Federica; Nebbioso, Marcella.
Afiliação
  • Limoli PG; Low Vision Research Centre of Milan, Piazza Sempione 3, 20145, Milan, Italy.
  • Limoli C; Low Vision Research Centre of Milan, Piazza Sempione 3, 20145, Milan, Italy.
  • Vingolo EM; Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.
  • Franzone F; Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.
  • Nebbioso M; Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy. marcella.nebbioso@uniroma1.it.
Stem Cell Res Ther ; 12(1): 275, 2021 05 06.
Article em En | MEDLINE | ID: mdl-33957957
ABSTRACT

BACKGROUND:

Glaucomatous optic neuropathy (GON) is an anatomofunctional impairment of the optic nerve triggered by glaucoma. Recently, growth factors (GFs) have been shown to produce retinal neuroenhancement. The suprachoroidal autograft of mesenchymal stem cells (MSCs) by the Limoli retinal restoration technique (LRRT) has proven to achieve retinal neuroenhancement by producing GF directly into the choroidal space. This retrospectively registered clinical study investigated the visual function changes in patients with GON treated with LRRT.

METHODS:

Twenty-five patients (35 eyes) with GON in progressive disease conditions were included in the study. Each patient underwent a comprehensive ocular examination, including the analysis of best corrected visual acuity (BCVA) for far and near visus, sensitivity by Maia microperimetry, and the study of the spectral domain-optical coherence tomography (SD-OCT). The patients were divided into two groups a control group, consisting of 21 eyes (average age 72.2 years, range 50-83), and an LRRT group, consisting of 14 eyes (average age 67.4, range 50-84).

RESULTS:

After 6 months, the BCVA, close-up visus, and microperimetric sensitivity significantly improved in the LRRT-treated group (p<0.05), whereas the mean increases were not statistically significant in controls (p>0.5).

CONCLUSIONS:

Patients with GON treated with LRRT showed a significant increase in visual performance (VP) both in BCVA and sensitivity and an improvement of residual close-up visus, in the comparison between the LRRT results and the control group. Further studies will be needed to establish the actual significance of the reported findings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Nervo Óptico / Glaucoma Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Stem Cell Res Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Nervo Óptico / Glaucoma Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Stem Cell Res Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália